ABSTRACT
This paper introduces two novel deep convolutional neural network (CNN) architectures for automated detection of COVID-19. The first model, CovidResNet, is inspired by the deep residual network (ResNet) architecture. The second model, CovidDenseNet, exploits the power of densely connected convolutional networks (DenseNet). The proposed networks are designed to provide fast and accurate diagnosis of COVID-19 using computed tomography (CT) images for the multi-class and binary classification tasks. The architectures are utilized in a first experimental study on the SARS-CoV-2 CT-scan dataset, which contains 4173 CT images for 210 subjects structured in a subject-wise manner for three different classes. First, we train and test the networks to differentiate COVID-19, non-COVID-19 viral infections, and healthy. Second, we train and test the networks on binary classification with three different scenarios: COVID-19 vs. healthy, COVID-19 vs. other non-COVID-19 viral pneumonia, and non-COVID-19 viral pneumonia vs. healthy. Our proposed models achieve up to 93.96% accuracy, 99.13% precision, 94% sensitivity, 97.73% specificity, and a 95.80% F1-score for binary classification, and up to 83.89% accuracy, 80.36% precision, 82% sensitivity, 92% specificity, and a 81% F1-score for the three-class classification tasks. The experimental results reveal the validity and effectiveness of the proposed networks in automated COVID-19 detection. The proposed models also outperform the baseline ResNet and DenseNet architectures while being more efficient.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work of the first and third authors was supported by the Deanship of Scientific Research at King Khalid University under grant number RGP.2/1/42. The work of Christoph Linse was supported by the Bundesministeriums fuer Wirtschaft und Energie (BMWi) through the Mittelstand 4.0-Kompetenzzentrum Kiel Project.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB/oversight body approval was required
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.